The ASICS trial is a non-inferiority, single-arm trial open to both breast-conserving and mastectomy patients in which no SLNB is performed in cN0, triple-negative, or HER2-positive breast cancer patients with a radiological complete response on MRI (30). This evidence concerns the gene ERBB2 and breast carcinoma.